ETFS Capital led the extension round, which will support the wealthtech provider's growth into European markets.
"We are pleased to provide further funding to WealthKernel. Having seen the business grow from strength to strength since we first invested in 2018, we look forward to supporting Karan and team as they continue this expansion into Europe. The demand for innovation in the wealth and asset management industry has never been higher, which WealthKernel is perfectly placed to deliver."
The financing round was led by Molten Ventures with backing from LifeX Ventures and private individuals.
"With our technology, we’re building the world’s largest immune data assets across health and disease, which allows us to perform analyses with a level of depth and granularity that was previously unthinkable. This systems-level approach to understanding immune function enables us to look at the bigger picture rather than just focusing on individual disease-associated parameters. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run."
— Adam Laing, President and Chief Scientific Officer
The Series A round was led by AlbionVC with backing from Dowgate Capital and private investors.
"We're building a category-defining business that redefines the way humans interact with technology and that makes advanced and Generative AI realizable for enterprises. Businesses are keen to take advantage of the technology they see manifested in applications like ChatGPT, but they're struggling to figure out how to make that a reality in a business context without exposing themselves to risks. We can offer them the security, granular control, explainability and safety which is essential for all businesses, but particularly those operating in regulated sectors like insurance, healthcare, financial services and utilities."
Plural led the Series A follow-on round to help the company scale its precision medicine platform and expand globally.
"Precision medicine is transforming how we think about and approach healthcare, and clinical trials are the bedrock of precision drug development. In the past 12 months, we’ve scaled up our capacity to hold three times more trials than the year before and launched our first programme supporting families affected by ALS. I’m so pleased with everything the team has achieved so far and this new funding will help us to integrate LLMs and other AI tools to drive more productivity. This will help us continue our growth trajectory, particularly with the help of visionary investors like Carina Namih, who supported our seed round and is now supporting us again at Plural."
The fitness dating brand raised funds backed by European champion powerlifter Nathaniel Massiah to support UK growth and US expansion.
"Having watched the FITFCK journey over the past year, I have not only been impressed by the overall growth of the brand but also their ability to create such a talked about fitness community. I think the concept of connecting like minded gym lovers is something that we can all relate to and I cannot wait to see what we can achieve together in 2024 and the future."
